CClinicalTrials.gg
Status unknownNCT01350687Updated May 10, 2011

Pulmonary Hypertension Prevention in Hemodialysis

An observational study in Chronic Kidney Disease, sponsored by The Baruch Padeh Medical Center, Poriya. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-05-10.

Sponsored by The Baruch Padeh Medical Center, Poriya · Observational

The sponsor has not verified this record recently (last verified Apr 2011), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Pulmonary hypertension is a new complication described in hemodialysis patients. in the last year these patients were treated by calcium carbonate orally to control serum phosphor. Calcium phosphor deposits in pulmonary artery can explain this phenomena. The investigators want to investigate the new phosphor non calcium containing agents in hemodialysis patients and to measure the pulmonary pressure.

Read the detailed description

The investigators will measure pulmonary blood pressure before and after treatment with new phosphor binders, non calcium containing.

02

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Calcium Phosphore
  • Renagel
03

In context

Hypertension, Pulmonary

1,105 studies on the registry are indexed under Hypertension, Pulmonary; 234 are open to participants now.

This study's planned enrollment of 40 is below the median of 116 across 386 observational studies indexed under Hypertension, Pulmonary.

Browse Hypertension, Pulmonary studies →

Lead sponsor

The Baruch Padeh Medical Center, Poriya is the lead sponsor of 39 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

40 patients on hemodialysis treated with Phosphore biders, non-calcium containig.

Inclusion criteria

  • Hemodialysis Patients without fistula

Exclusion criteria

Exclusion Criteria:

  • Heart Disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
06

Study locations

1 site
  • Poria Medical Center
    Tiberias, Israel
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01350687
Lead sponsor
The Baruch Padeh Medical Center, Poriya
First posted
May 10, 2011
Start date
Jun 2011
Primary completion
Jun 2013 (estimated)
Completion
Jun 2014 (estimated)
Last update
May 10, 2011

Study contacts

Farid Nakhoul, Prof.
study chair · Poria medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion